DNA encapsidation as a target for anti-herpesvirus drug therapy

The current repertoire of approved anti-herpesviral drugs consists primarily of nucleoside analogues that inhibit viral replication by targeting the virus-encoded DNA polymerase. This class of agents has been critical in controlling infections by herpes simplex, varicella zoster, and cytomegalovirus...

Full description

Saved in:
Bibliographic Details
Published in:Antiviral Research 2003-07, Vol.59 (2), p.73-87
Main Authors: Visalli, Robert J., van Zeijl, Marja
Format: Article
Language:English
Subjects:
Amino Acid Sequence
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral
Antiviral agents
Antiviral Agents - chemistry
Antiviral Agents - pharmacology
Biological and medical sciences
DNA, Viral - drug effects
DNA, Viral - genetics
Drug Design
Encapsidation
Herpesviridae - drug effects
Herpesviridae - genetics
Herpesviridae - physiology
Herpesviridae Infections - drug therapy
Herpesviridae Infections - virology
Herpesviruses
Humans
Medical sciences
Microscopy, Electron
Molecular Sequence Data
Mutation
Pharmacology. Drug treatments
Portal
Sequence Homology, Amino Acid
Viral Proteins - genetics
Virus Assembly - genetics
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The current repertoire of approved anti-herpesviral drugs consists primarily of nucleoside analogues that inhibit viral replication by targeting the virus-encoded DNA polymerase. This class of agents has been critical in controlling infections by herpes simplex, varicella zoster, and cytomegalovirus. However, because nucleoside analogues share a similar mechanism of action, treatment options are limited once resistance develops. This becomes an important medical issue with respect to the treatment of disease caused by resistant viral strains, particularly in immunocompromised individuals. Furthermore, several of the currently available therapies can result in mild to severe side effects making the discovery of less toxic drugs desirable. Efforts over the last decade have focused on the identification and development of improved therapies including less toxic compounds with novel mechanisms of action. Here we review the progress that has been made in targeting the DNA packaging and encapsidation process as a novel target for chemotherapy. Several recently identified compounds may warrant further development as a medically important group of herpesviral encapsidation inhibitors.
ISSN:0166-3542
1872-9096
DOI:10.1016/S0166-3542(03)00108-6